Virgil has substantial benefits for sponsors and CROs, as it reduces administrative burden, mitigates cost, and speeds trials. Such a system shows strong results with fewer errors and discrepancies, improved data quality, clearer signals, and standardized, accurate studies.
The ultimate beneficiaries of clearer signals and reduced administrative burden are of course CNS patients and their families. Their quality of life depends on medical advances; advances that improvements in the clinical trial process have vast potential to accelerate.
CHART DATA SOURCE: Negash S, et al. Virgil investigative study platform minimizes scoring discrepancies to improve signal detection. Presented at AAIC 2016, Toronto, Canada. F(1,298) = 38.4 p<.0001